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(Behtash et al., 2003). Embryonal rhabdomyosarcoma (RMS) is
extremely rare. We present the second reported case in pregnancy,
and describe management of a FIGO 1B1 tumour in pregnancy
where a delivery delay was desired. The chemotherapy used pertains
to the recommended regime for RMS which is mostly extrapolated
from paediatric evidence (Zeisler et al., 1998; Brand et al., 1987). It
is the 38th reported case of cervical cancer in pregnancy where
neoadjuvent chemotherapy (NACT) has been adopted in order to
achieve foetal lung maturity. It is the ﬁrst case of RMS in pregnancy
where NACT has been used.CaseIntroduction
Cancer affects approximately 1 in 1000 pregnancies and is expected
to become increasingly common. The most frequently diagnosed
cancers in pregnancy include breast cancer, cervical cancer, melanoma,
lymphoma and leukaemia (Meseci et al., 2014). Cervical cancer makes
up approximately 25% of cancers diagnosed in pregnancy (Meseci
et al., 2014). Nevertheless, the literature to inform evidence-based
practice in this situation remains limited. The management approach
in many circumstances is extrapolated from case studies involving
non-pregnant women.
There are many factors which may be associated with this alarming
trend including; delaying pregnancy into later reproductive years, the
potential inﬂuence that pregnancy has on tumour growth, and the
increased likelihood of diagnosis associated with increased interaction
with health services (Meseci et al., 2014).
The most common subtypes of cervical cancer are squamous cell
carcinoma and adenocarcinoma, making up approximately 95% of
cases (Behtash et al., 2003). More rare varieties include small cell,avi).
. This is an open access article underA 36 year old, with a history of spotting since 13weeks, presented at
20 weeks of gestation with heavy bleeding and passing “grape-like”
tissue. On examination she had a 4 cm exophytic lesion on her cervix
which was very friable. Abdominal ultrasound scan was normal
and showed no extension of the cervical lesion. Examination under
anaesthetic was performed with excision of the mass under spinal an-
aesthesia. A histological diagnosis of cervical embryonal rhabdomyosar-
coma (botryoides) was made (Fig. 2).
With a normal cervical smear history prior six months before the
above diagnosis, she had been referred for review of a large cervical
polyp. At this time, the lesion appeared clinically and histologically
benign (Fig. 1). However, when reviewed again at the time of diagnosis,
this was also noted to be embryonal rhabdomyosarcoma. Her obstetric
history included two previous caesarean sections (her children
now aged four and one), a previous termination of pregnancy for an
anencephalic baby, and one ﬁrst trimester miscarriage.
Staging investigations,MRI and CXR, performed at 24weeks showed
no evidence ofmetastatic disease.Multi-disciplinary-team reviewpanel
recommended, six rounds of chemotherapy starting antenatally with
vincristine (1.4 mg m−2), adriamycin (0.75 mg m−2), and cyclophos-
phamide (1500 mg m−2). During each round, these three medications
were administered within 2 days and there were 21 days between
each round of chemotherapy. Delivery with caesarean, radical hysterec-
tomy and nodal clearance were performed at 34 weeks. The ﬁnalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. First cervical polyp, early disease: under low power, high power and myogenin stain.
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continued.
Antenatally, our patient was seen weekly, with alternating obstetric
and gynae-oncology reviews. Fortnightly growth scanswere performed
and weekly biophysical proﬁles during the period of antenatal
chemotherapy. No signiﬁcant foetal or maternal complications were
encountered antenatally. Post-operatively, after the 4th round of
chemotherapy she was admitted with mild neutropenia and a pelvic
vault collection that was drained. She also suffered a transient period
of moderate short term memory impairment. All of these issues
resolved and the patient has remained free from disease to date. Her
child had no signiﬁcant neonatal complications and all developmental
milestones have been met to 2 years follow-up.
Discussion
The case represents the second case of embryonal rhabdomyosarco-
ma (RMS) in pregnancy. In another recently described case, a FIGO stage
1A embryonal RMSwas diagnosed at 30weeks of gestation. Interesting-
ly, there was a delay in diagnosis in this case too as a polyp noted at
6 weeks was initially thought benign (Meseci et al., 2014). In this case
the decision was made to delay treatment until foetal lung maturity
was achieved at 34weeks. Then, a caesarean sectionwith radical hyster-
ectomy, pelvic para-aortic lymphadenectomywas performed and adju-
vant chemotherapy subsequently commenced.
RMS is extremely rare in absolute numbers and is classically seen in
infants or young children. In this age group, it accounts for 4–6% of
malignancies (Zeisler et al., 1998; Behtash et al., 2003). The mean age
at diagnosis is two years and 90% of cases will occur prior to the age of
ﬁve (Singhal et al., 1990). A recent case series of all documented cases
reports 8 cases in women of reproductive age. RMS is classiﬁed into
three sub-types: embryonal, alveolar and pleomorphic (Behtash et al.,
2003). RMS can arise anywhere, the most common locations being the
head and neck (40%), the genitourinary tract (25%) and the extremities
(20%) (Dehner et al., 2012). A subtype of the embryonal category isFig. 2. EUA biopsies — 4 cm exophyitic lesion now visible on exbotryoides (which describes the grossly polypoid “grape like” appear-
ance) ﬁrst described by Pfannensteil in 1892 (Zeisler et al., 1998).
The botryoid subtype is generally found in the vagina during early
childhood, the cervix in adolescence and in the uterus during post-
menopausal years (Dehner et al., 2012; Zeisler et al., 1998; Behtash
et al., 2003; Brand et al., 1987; Daya and Scully, 1988).
Diagnosis can be very complicated. Pathological ﬁndings in the early
stages of disease may be obscure and a high level of suspicion is
required to guide investigations. Themicroscopic ﬁndings in embryonal
RMS are relatively consistent irrespective of the organ involved. Includ-
ing ours, ﬁve cases of cervical disease have encountered a delay in
diagnosis (Zeisler et al., 1998; Behtash et al., 2003; Garrett et al.,
2013). No clear diagnostic features in the early stage of disease have
been described in the literature (Garrett et al., 2013). A foci of increased
cellularity, indicative of neoplasm, may be the only distinguishing
feature and lead to the observed delay in diagnosis (Dehner et al.,
2012; Singhal et al., 1990; Zeisler et al., 1998). The differential diag-
nosis for polypoid spindle cell lesions of the cervix in adult women
can be broad and includes endometriosis, cervical or endometrial
polyps, adenofribroma, adenosarcoma, mesodermal polyps, small
cell carcinoma and lymphoma. Distinguishing features would in-
clude rhabdomyoblasts of varying differentiations (which may be
dispersed with loose myxoid stroma) and a cambium layer. Cartilag-
inous differentiation is also a feature in many cases.
Histopathological features associated with poor prognosis include
deep myometrial invasion, lymphatic invasion and focal alveolar
pattern (Singhal et al., 1990). Data regarding cytogenetics and heritabil-
ity of the disease is limited and may comprise a rare cluster of inherit-
able soft tissue malignancies called the Li-Fraumeni syndrome
(Mousavi and Akhavan, 2010). Only one case of embryonal RMS has
been cytogenetically analysed (Palazzo et al., 1993). Cervical embryonal
RMS has been reported in sisters at age 15 and 17 respectively (Mousavi
and Akhavan, 2010). Unfortunately genetic information from these
cases is not available. The signiﬁcance of these ﬁndings on their own
is limited but it does highlight the importance of having new casesamination: low, medium and high power, desmin staining.
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medicine, individualising treatment based on cytogenetics is increas-
ingly relevant.
Treatment of RMS has evolved considerably over the past several
decades. Management of the disease in adults is guided by the paediat-
ric literature and recommendations developed by The Soft Tissue
Sarcoma Committee of the Children's Oncology Group (Zeisler et al.,
1998). They suggest complete excision for localized disease. If not
feasible, an initial diagnostic biopsy followed by NACT, then deﬁnitive
local therapy is suggested, however, there are no cases of this in the
adult cohort. Using combined modality therapy, 70–90% of patients
with localized RMS achieve cure. Radiation therapy can enhance local
control in patients with residual microscopic or gross disease following
surgery.
All reported cases of embryonal RMS in the literature have been
managed with primary surgery and subsequent chemotherapy/radio-
therapy (Dehner et al., 2012; Singhal et al., 1990; Zeisler et al., 1998;
Behtash et al., 2003; Brand et al., 1987; Daya and Scully, 1988; Garrett
et al., 2013; Mousavi and Akhavan, 2010). Management in pregnancy
is challenging as deliberate delay raises concerns for maternal morbidi-
ty, especially when the diagnosis occurs in the ﬁrst and second trimes-
ter. The principles guiding care include the evaluation of tumour size
and stage, nodal status, gestation, parental wishes regarding the
pregnancy, and histological subtype. This is the ﬁrst time that NACT
has been used and our case suggests good maternal and foetal
outcomes. NACT followed by radical hysterectomy has emerged in
recent years as an alternative to allow foetal lung maturation in
pregnancy (Pettersson et al., 2010). 37 cases of NACT have been
described in women with cervical cancer in pregnancy who have FIGO
stage N1B1. The advantages of this approach include the opportunity
to evaluate the efﬁcacy of the drugs after each cycle, a reduction of the
tumour burden to make it operable, and the theoretical treatment of
nodal micrometastasis (Pettersson et al., 2010).
Evaluation of the efﬁcacy and safety of NACT in pregnancy is not easy
for several reasons but primarily due to the limited number of cases
reported in the literature. The cases described to date predominantly
involve squamous cell carcinoma and adenocarcinoma (n = 29 78%)
(Youseﬁ et al., 2013). Most cases used single therapy cisplatin with
good effect and safety (Youseﬁ et al., 2013). The chemotherapy regime
of paclitaxel, ifosfamide and cisplatin is not recommended due to the
nephrotoxic effect of ifosfamide on the foetus (Youseﬁ et al., 2013).
Seven cases used the combination of cisplatin and paclitaxel, and in
one case this combinationwas associatedwith a severe allergic reaction
leading to the onset of pre-term labour (Youseﬁ et al., 2013). The regime
used in our case looked at the use of vincristine, dactinomycin and
cyclophosphamide. These drugs have been extensively studied in
animals but human data is sparse. Fewer than 10 cases describe the
use of each of these medications in pregnancy and this limited data
suggests that in the second and third trimesters there is a reduced like-
lihood of congenital malformations (Kirshon et al., 1988; Nicholson,
1968). Associated problems may include craniofacial dysmorphisms,
growth restriction, pancytopenia or foetal demise (Kirshon et al.,
1988; Nicholson, 1968).
In considering delivery delay, the effect of pregnancy on the tumour
and progression of disease is of fundamental importance. To date there
is no evidence that pregnancy itself worsens the prognosis for patients(Pettersson et al., 2010). Many studies show no signiﬁcant difference
in survival between pregnant and non-pregnant women who are
matched by age stage and histopathology (Pettersson et al., 2010).
There is growing evidence for the use of NACT as an option for women
with invasive cervical cancerwhodonotwish to sacriﬁce their pregnan-
cy (Youseﬁ et al., 2013). Therefore, management in a multi-disciplinary
team is required with comprehensive counselling regarding the full
spectrum of management options. Particular care and monitoring are
required when FIGO stage 1B2 or higher occurs to ensure that there is
a favourable response to treatment and no signs of progression. Our
case is the 38th case where NACT has been used and the ﬁrst case of
embryonal RMS in pregnancy. The results have been most promising.
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